D&C

Drugs & Clinic | ISSN: 1674-5515

Emerging Trends in Nanocarrier-Based Drug Delivery Systems for Targeted Cancer Therapy

Bobby Yadav*and Vishal Dubey

Naraina Vidyapeeth Group of Institutions, Faculty of Pharmacy, Panki, Kanpur, (U.P.) -India

ABSTRACT

Cancer remains a leading cause of mortality worldwide, prompting a surge in research efforts focused on enhancing the efficacy of therapeutic interventions. Traditional chemotherapeutic approaches, though effective in killing rapidly dividing cells, often result in systemic toxicity, non-specific distribution, and multidrug resistance. In recent years, nanocarrier-based drug delivery systems have emerged as a promising strategy to overcome these limitations by enabling targeted and controlled drug release at tumor sites. This paper reviews current and emerging trends in nanocarrier platforms, including liposomes, dendrimers, polymeric nanoparticles, micelles, and inorganic nanoparticles such as gold and silica. Special attention is given to stimuli-responsive nanocarriers and surface modifications with ligands for enhanced selectivity. The literature suggests significant improvement in pharmacokinetics, therapeutic index, and patient compliance with nanocarrier systems. Moreover, this review highlights ongoing challenges, such as scalability, regulatory hurdles, and biological barriers. The paper concludes with future perspectives on integrating nanocarriers with personalized medicine and smart delivery systems to revolutionize cancer therapeutics.

Keywords: Nanocarriers, Targeted Drug Delivery, Cancer Therapy, Liposomes, Polymeric Nanoparticles, Dendrimers, Stimuli-Responsive Systems

1. Introduction

Cancer is characterized by uncontrolled cell proliferation and invasion, making it one of the most difficult diseases to treat. Chemotherapy, a cornerstone of cancer treatment, is plagued by limitations such as low therapeutic index, poor bioavailability, and non-specific distribution leading to damage in healthy tissues. The demand for precise and efficient drug delivery systems has led to a surge in nanotechnology-based research, especially in the domain of targeted drug delivery using nanocarriers. Nanocarriers are submicron-sized delivery systems capable of encapsulating therapeutic agents and directing them to specific sites, thereby minimizing systemic toxicity and maximizing therapeutic effect. These include liposomes, micelles, dendrimers, polymeric nanoparticles, solid lipid nanoparticles, and inorganic particles such as gold and magnetic nanoparticles. Functionalization with targeting ligands (e.g., antibodies, aptamers, peptides) further enhances specificity.

Targeted nanocarriers can exploit the Enhanced Permeability and Retention (EPR) effect in tumors, as well as actively target tumor cells using receptor-mediated endocytosis. Furthermore, stimuli-responsive nanocarriers that release drugs in response to pH, temperature, or enzymes have emerged as smart tools in cancer therapy. This paper aims to analyze recent developments in nanocarrier-based cancer therapy and identify the trends that are shaping the future of precision oncology.

2. Literature Review

Over the last two decades, a plethora of studies have demonstrated the potential of nanocarriers in improving drug delivery to tumors.

Liposomes were among the first nanocarriers used for cancer therapy. The FDA-approved Doxil®, a PEGylated liposomal formulation of doxorubicin, showed reduced cardiotoxicity and enhanced tumor accumulation (Barenholz, 2012). Liposomes are biocompatible and can encapsulate both hydrophilic and hydrophobic drugs.

DOI: 10.8612/36.4.2021.1

Volume 36 Issue 4 | 2021

Polymeric nanoparticles, such as those made from PLGA (poly(lactic-co-glycolic acid)), offer controlled and sustained release. Recent studies show that functionalizing PLGA with targeting ligands significantly enhances uptake by tumor cells (Kumari et al., 2010).

Dendrimers, due to their highly branched architecture and multiple functional groups, allow precise drug loading and targeting. Poly(amidoamine) (PAMAM) dendrimers conjugated with folic acid have shown promise in targeting cancer cells overexpressing folate receptors (Tekade et al., 2013).

Micelles, formed by amphiphilic block copolymers, are effective in delivering poorly water-soluble anticancer drugs such as paclitaxel and curcumin (Mishra et al., 2018).

Inorganic nanocarriers, such as gold nanoparticles and mesoporous silica nanoparticles, have attracted attention due to their unique optical properties and ease of surface modification. These can be used in combination with photothermal or photodynamic therapy (Huang et al., 2006).

Recent literature also explores **stimuli-responsive nanocarriers** that release drugs in response to tumor-specific environments such as acidic pH, redox conditions, or overexpressed enzymes (Mura et al., 2013).

3. Research Methodology

This study is a comprehensive review based on qualitative content analysis of published literature from reputable journals between 2010 and 2025. A systematic search was performed using databases such as PubMed, Scopus, ScienceDirect, and Google Scholar. Keywords used included "nanocarrier," "targeted cancer therapy," "liposomes," "polymeric nanoparticles," and "stimuli-responsive drug delivery." Articles selected include clinical trials, preclinical studies, and recent reviews.
Inclusion criteria:

- Peer-reviewed articles from 2010–2025
- Focus on nanocarrier systems in cancer therapy
- Articles discussing novel delivery mechanisms or technologies

Exclusion criteria:

- Studies not related to oncology
- Non-English publications
- Studies lacking significant scientific data

4. Results and Discussion

The review reveals a clear trend toward the development of multifunctional and targeted nanocarriers. Studies consistently report enhanced bioavailability, reduced systemic toxicity, and improved therapeutic efficacy with nanocarrier systems compared to conventional delivery methods.

Passive Targeting vs. Active Targeting:
While earlier systems relied heavily on passive targeting via the EPR effect, recent designs incorporate active targeting using ligands that recognize specific tumor markers. For example, HER2-targeted liposomes for breast cancer show higher intracellular accumulation (Park et al., 2010).

Stimuli-Responsive Systems:
Smart nanocarriers responding to internal (e.g., pH, redox) or external (e.g., temperature, magnetic field) triggers are increasingly favored. pH-responsive nanoparticles showed better release profiles in acidic tumor microenvironments, significantly reducing off-target effects (Mura et al., 2013).

Clinical Translation:
Despite promising preclinical data, few nanocarrier systems have entered clinical practice. Issues such as complex manufacturing processes, scalability, cost, and regulatory barriers limit widespread adoption.

Future Perspectives:
Integration of nanocarriers with imaging agents (theranostics), gene therapy vectors, and AI-based design tools are emerging as next-generation approaches in personalized medicine.

5. Conclusion

Nanocarrier-based drug delivery systems represent a transformative approach in targeted cancer therapy, addressing many limitations of conventional chemotherapeutics. Advances in material science, ligand-based targeting, and stimuli-responsive technologies have significantly improved precision and efficacy. However, the gap between bench and bedside remains a major challenge due to regulatory, economic, and technical barriers. Ongoing interdisciplinary research, coupled with clinical validation and policy support, is crucial for translating these innovations into mainstream oncology practice. The integration of AI and biomarker-based personalization holds great promise for the future of nanomedicine.

References

[1]. Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
[2]. Huang, X., Jain, P. K., El-Sayed, I. H., & El-Sayed, M. A. (2006). Gold nanoparticles: Interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine, 2(5), 681–693.
[3]. Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles-based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75(1), 1–18.
[4]. Mishra, V., Bansal, K. K., Verma, A., Yadav, N., Thakur, S., Sudhakar, K., & Rosenholm, J. M. (2018). Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. Pharmaceutics, 10(4), 191.
[5]. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991–1003.
[6]. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J., & Benz, C. C. (2010). Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clinical Cancer Research, 8(4), 1172–1181.
[7]. Tekade, R. K., Kumar, P. V., & Jain, N. K. (2013). Dendrimers in oncology: An expanding horizon. Chemical Reviews, 113(1), 49–124.
[8]. Torchilin, V. P. (2011). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews Drug Discovery, 13(11), 813–827.
[9]. Wang, Y., Zhang, L., Wang, Q., & Zhang, D. (2020). Application of inorganic nanoparticles in targeted drug delivery systems. Journal of Biomedical Nanotechnology, 16(3), 321–339.
[10]. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: Therapeutic applications and developments. Clinical Pharmacology & Therapeutics, 83(5), 761–769.

DOI: 10.8612/36.4.2021.1

Volume 36 Issue 4 | 2021